Department of Surgery, Columbia University Medical Center, New York, NY.
Department of Medicine, Columbia University Medical Center, New York, NY.
Transplantation. 2018 Oct;102(10):1603-1613. doi: 10.1097/TP.0000000000002239.
Despite decades of research, the induction and maintenance of long-term allograft tolerance without immunosuppression remains an elusive goal in the field of solid organ and cell transplantation. Immunosuppressive medications frequently prevent or minimize acute cellular rejection but have failed to halt antidonor antibody production and chronic organ rejection. Past efforts aimed at promoting lasting allograft tolerance have focused primarily on peripheral T-cell depletion, augmentation of regulatory T cells, or induction via simultaneous hematopoietic stem cell transplantation and facilitation of donor chimerism. So far, none of these methods have led to consistently safe, feasible and long lasting donor organ acceptance. Over the course of the past 4 decades, the study of a unique population of antigen-presenting cells known as dendritic cells has shown promise for breaking new ground in achieving indefinite allograft survival without immunosuppression and its associated adverse effects. In this review, we discuss the discovery and early investigations of dendritic cells and chronicle some of the key studies demonstrating their role in transplantation, particularly in indirect allorecognition, the immunologic pathway thought to drive chronic rejection and perhaps tolerance induction.
尽管已经进行了数十年的研究,但在实体器官和细胞移植领域,仍然难以实现无需免疫抑制就能诱导和维持长期同种异体移植物耐受。免疫抑制药物常常可以预防或最小化急性细胞排斥反应,但未能阻止抗供体抗体的产生和慢性器官排斥反应。过去旨在促进持久同种异体移植物耐受的努力主要集中在外周 T 细胞耗竭、调节性 T 细胞的增强,或通过同时进行造血干细胞移植和促进供体嵌合来诱导。到目前为止,这些方法都没有导致一致的、安全的、可行的和长期的供体器官接受。在过去的 40 年中,对一种称为树突状细胞的独特抗原呈递细胞群体的研究表明,在不使用免疫抑制及其相关副作用的情况下实现无限期同种异体移植物存活方面有很大的希望。在这篇综述中,我们讨论了树突状细胞的发现和早期研究,并记录了一些关键的研究,这些研究证明了它们在移植中的作用,特别是在间接同种异体识别中,这一免疫途径被认为是导致慢性排斥反应的原因,也许还能诱导耐受。